S. Susen
Susen, Sophie, 1964-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 206109566 ( Personal )
Permalink: http://viaf.org/viaf/206109566
Preferred Forms
-
100 0 _
‡a
S. Susen
-
100 1 _
‡a
Susen, Sophie
‡d
1964-...
-
100 1 _
‡a
Susen, Sophie,
‡d
1964-....
4xx's: Alternate Name Forms (3)
Works
| Title | Sources |
|---|---|
| Athérosclérose et sténose valvulaire aortique : implication des macrophages et des cellules interstitielles de valve dans les calcifications cardiovasculaires |
|
| Cellular circulating biomarkers of endothelial dysfunction : detection and vascular potential. |
|
| Characterization of new mediators between cancer, inflammation and thrombosis : ADAMTS13 , PSGL -1 and Siglec -5. |
|
| Clinico biological data to create a pharmacokinetics/pharmacodynamic model of tranexamic acid during hemorrhagic cesarean section. |
|
| Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19 |
|
| Complications ischémiques et hémorragiques des procédures de réparation valvulaire aortique percutanée |
|
| Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factor. |
|
| [Direct oral anticoagulant associated bleeding]. |
|
| Données clinico-biologiques en vue d'une modélisation pharmacocinétique et pharmacodynamique de l'acide tranéxamique chez la femme au cours d'une césarienne hémorragique |
|
| Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques |
|
| Egfl7 Represses the Vasculogenic Potential of Human Endothelial Progenitor Cells. |
|
| Endothelial progenitor cells are selectively mobilised immediately after coronary artery bypass grafting or valve surgery |
|
| Evaluation du risque hémorragique chez des patients atteints de sténose aortique : résultats d'une étude multicentrique |
|
| Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. |
|
| Facteurs biologiques et morphologiques prédictifs de récurrences ischémiques et hémorragiques dans l'athéro-thrombose |
|
| La fibrinographie : une méthode multi-longueurs d'ondes pour la détermination de la structure du caillot en plasma |
|
| Fibrinography : a multiwavelength light-scattering assay of fibrin formation in plasma. |
|
| From normal to pathological hemostasis. |
|
| Gastrointestinal bleeding from angiodysplasia in von Willebrand disease: improved diagnosis and outcome prediction using videocapsule on top of conventional endoscopy |
|
| Hemostasis and Thrombosis: Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia |
|
| High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure |
|
| [Hormone replacement therapy and venous thromboembolism] |
|
| Identification of tissue factor in experimental aortic valve sclerosis. |
|
| Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules |
|
| Impact of inflammation on post procedural complications after TAVR : role of monocytes and clonal hematopoiesis of indeterminate potential. |
|
| Impact of initial clinical presentation on clopidogrel low response |
|
| In Response |
|
| Inflammation triggers colony forming endothelial cell mobilization after angioplasty in chronic lower limb ischemia |
|
| Intérêt de l’étude des anomalies de multimérisation du facteur Willebrand pour l’identification des insuffisances aortiques post-TAVI |
|
| Intérêt de la vectorisation du t-PA au thrombus : exemple du Fucoidan aminé |
|
| Ischemic and haemorrhagic complications during percutaneous aortic valve interventions. |
|
| Lésions endothéliales liées à un défaut de contrôle du complément : de la génétique du complément au syndrome hémolytique et urémique |
|
| M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes |
|
| [Management of massive bleeding in 2013: seven questions and answers] |
|
| Marqueurs d’endothéliopathie dans une population de traumatisés graves : données de l’étude TRAUCC |
|
| Mécanismes cellulaires et moléculaires de la thrombose : de l'implication des polynucléaires neutrophiles et des NETs |
|
| Mécanismes et Conséquences de l'Oedème Cérébral sur le Pronostic des Hémorragies IntraCérébrales Spontanées |
|
| Medical advances in the treatment of postpartum hemorrhage |
|
| MISE EN EVIDENCE DE L'EXPRESSION DU FACTEUR TISSULAIRE PAR LES MONOCYTES SANGUINS : COMPARAISON DE TECHNIQUES IMMUNOLOGIQUES ET FONCTIONNELLES |
|
| Modélisation de la thrombose dans des dispositifs médicaux. |
|
| Modulation du potentiel angiogène des progéniteurs endothéliaux humains par des biomarqueurs plasmatiques vasculaires |
|
| The place of fibrinogen concentrates in the management of perioperative bleeding: A position paper from the Francophone Working Group on Perioperative Haemostasis (GIHP) |
|
| premature coronary atherosclerosis : risk factors, prognosis, prevention and novel mechanistics approaches. |
|
| The presence of apoptotic bone marrow cells impairs the efficacy of cardiac cell therapy. |
|
| Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring |
|
| Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure |
|
| Prognostic value of hemoglobin decline over the GRACE score in patients hospitalized for an acute coronary syndrome. |
|
| [Prophylaxis of thromboembolic events during urologic surgery] |
|
| Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets |
|
| Protéolyse du facteur Willebrand et cardiopathies à forces de cisaillement élevées : nouvelles approches diagnostiques et thérapeutiques |
|
| The proteome and secretome of human arterial smooth muscle cells |
|
| Relevance of tissue factor in cardiovascular disease |
|
| Response to letter regarding article, "postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: analysis of predictors and impact on long-term mortality: insights from the FRANC |
|
| Rôle du facteur tissulaire et du facteur Willebrand dans la réponse à différentes formes d'agression : modification des forces de cisaillement, athérosclérose, inflammation |
|
| Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization. |
|
| Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation |
|
| Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. |
|
| Structure analysis of the physiological or pathological clot. |
|
| Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemo |
|
| Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. |
|
| Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled t |
|
| Thrombosis modeling in blood coated medical devices |
|
| Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. |
|
| Transducin-like enhancer of split-1 is expressed and functional in human macrophages. |
|
| [Transfusion and postpartum haemorrhage]. |
|
| Trauma-induced coagulopathy |
|
| Treatment of massive bleeding with prothrombin complex concentrate: argument against. |
|
| Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. |
|
| Vascular thiol isomerases : targeting and regulation |
|
| Von Willebrand disease: Clinical conundrums |
|
| von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment |
|
| VWF proteolysis and high-shear cardiovascular disorders : new diagnosis and therapeutic approaches. |
|
